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Purpose of the study
Current guidelines recommend drug resistance (DR) test-
ing before the initiation of therapy. The aim of this study
was to assess the prevalence of DR mutations among
newly infected and cART experienced persons in Poland
and compare them with the values obtained in the years
2006 and 2002–2005.
Methods
The sequencing of protease and part of reverse tran-
scriptase region was performed using Trugene or ViroSeq
assay. The prevalence of drug resistance mutations was
estimated according to mutation list created for epidemi-
ological estimates of transmitted resistance [1]. Class
resistance was defined as the presence of at least one
mutation associated with resistance to any drug in that
class.
Summary of results
The study included 103 treatment naïve and 123 were
cART experienced persons. In the treatment naïve group,
the prevalence of transmitted DR was 3.9% (5.8% in 2006
and 14.1% in 2002–2005) and in all cases limited to sin-
gle classes. Mutations associated with resistance to NRTIs
and to NNRTIs were present in 1.9% of cases each. No
transmitted resistance to PIs was detected. In the cART
experienced group, the prevalence of DR mutations
reached 43.1% (52.6% in 2006 and 76.7% in 2002–
2005). Most of the virus variants were resistant to two
classes of drugs (28%), followed by resistance to one class
(13%). In two cases a three-class resistant strain was
detected (1.6%). The most common were mutations asso-
ciated with resistance to NRTIs (38%), followed by
NNRTIs (24%) and PIs (15%).
Conclusion
The prevalence of DR mutations in both analyzed groups
decreased when compared to previous studies from 2006
and 2002–2005. It may be the effect of more effective
antiretroviral drugs, incorporation of GT results into clin-
ical practice, and/or growing awareness of the role of
adherence. Transmission of DR mutations in Poland is
limited to single classes which is concordant with the
results of a study conducted by the SPREAD programme
in Europe [2]. The publication of standardized lists of
HIV-1 protease and reverse transcriptase mutations for DR
surveillance [1] facilitates the comparison of results
obtained in different countries.
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